ImpediMed Limited
10
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Subclinical Lymphedema Treatment Study
Role: collaborator
Body Composition During Cancer Treatment
Role: collaborator
Body Composition Post Cancer Treatment
Role: collaborator
Observational Study of BIS in Hemodialysis Patients
Role: lead
The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device
Role: lead
Home-Based Fluid Status Monitoring in Heart Failure Patients
Role: lead
Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)
Role: lead
Correlation of SOZO BIS Measures With CardioMEMS PA Pressure
Role: lead
Bioimpedance Spectroscopy Compared to CardioMEMS™
Role: lead
Assessment of Unilateral Lymphoedema of the Leg
Role: lead
All 10 trials loaded